Month: March 2025

SALT LAKE CITY, March 31, 2025 (GLOBE NEWSWIRE) — Security National Financial Corporation (SNFC) (NASDAQ symbol “SNFCA”) announced financial results for the year ended December 31, 2024. For the twelve months ended December 31, 2024, SNFC’s after-tax earnings from operations increased 83% from $14,495,000 in 2023 to $26,536,000 in 2024, on a 5% increase in revenues to $334,523,000. Scott Quist, Chairman of the Board, President, and Chief Executive Officer of SNFC, said, “2024 marked another year of solid progress for our Company. Our Life Insurance Segment had its best operational year ever, delivering a 25% improvement over 2023 which was its previous best year ever. We believe there is much opportunity for growth as we evaluate our competitive positions, improve the value propositions for our sales force, and increase...

Operating Expenses Decreased by 57.4% in 2024; Operating Loss Improved by 76.5% in 2024  Kartoon Channel Continues Growth in Viewers, Platforms, Revenue, and Profitability While Continuing to Lead All Streamers in Viewer Rankings in Apple App Store The Company’s Family and Kids’ Ad Unit, Beacon Media Group, Achieved Profitability in 2024 with High-Efficiency Ads and Data-Driven Strategies, Poised for Continuing Growth in 2025 Upcoming Animated Series, Hundred Acre Wood’s Winnie and Friends, and Stan Lee Universe’s The Excelsiors, Poised for Broad Launches in 2025 and 2026 BEVERLY HILLS, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Kartoon Studios (NYSE American: TOON) today provided a business update for the fourth quarter of 2024, highlighting continued momentum in revenue growth across all units, substantial improvements in cost...

QUEBEC CITY, March 31, 2025 (GLOBE NEWSWIRE) — Robex Resources Inc. (“Robex” or the “Company“) (TSXV: RBX) today reported its operational and financial results for 2024. Matthew Wilcox, Managing Director, commented: “2024 was a transformative year for Robex and we have achieved a lot to deliver shareholder value. The transition to the new board and management was executed and I look forward to 2025 with the first pour at Kiniero.” CURRENCY Unless otherwise indicated, all references to “$” in this news release are to Canadian dollars. References to “US$” in this news release are to U.S. dollars. RESULTS HIGHLIGHTSSafety: the Group accumulated 5.2 million hours worked without injury with lost time work, (the “Group” refers to the Company collectively with one,...

The Company Reports Continued Growth in Annual Revenue PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) — Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services, and proprietary medical products, today announced its operating results for the three months and year ended December 31, 2024. “Continuing the trend of top-line growth, the Company’s annual revenue reached another record of $86.8 million for the fiscal year 2024, an increase of $5.7 million or 7% when compared to the prior year’s revenue,” commented Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “Gross profit for 2024 was $52.1 million, up by $1.5 million or 3% year-over-year, and net income for 2024 decreased to $1.3 million from...

Earnings Call Webcast to Discuss 2024 Fourth Quarter and Full Year Financial Results Scheduled to Post to Corporate Website by Wednesday, April 2, 2025 NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) — Reading International, Inc. (NASDAQ: RDI) (“Reading” or our “Company”), an internationally diversified cinema and real estate company with operations and assets in the United States, Australia, and New Zealand, today announced its results for the fourth quarter and year ended December 31, 2024. Key Financial Results – Fourth Quarter 2024 compared to Fourth Quarter 2023Total Revenues increased by 29.3% (or $13.3 million) to $58.6 million compared to $45.3 million. Operating Loss of $7.0 million in last year’s quarter improved to an Operating Income of $1.5 million. Net Loss of $12.4 million in last year’s quarter was reduced to $2.2 million,...

Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise Unveiled rapid clinical development program for rademikibart initially targeting acute care in asthma and COPD; expect to initiate parallel Phase 2 trials in 2Q 2025 with data expected in 2H 2026 Strong balance sheet with cash runway into 2027 and through key clinical catalysts SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD), today reported financial results for the year ended December 31, 2024,...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, March 31, 2025 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) released its’ fourth quarter and year-end results today. The audited consolidated financial statements, management discussion & analysis (“MD&A”), and annual information form for the year ended December 31, 2024 will be available on SEDAR at www.sedar.com, and on High Arctic’s website at www.haes.ca. All amounts are denominated in Canadian dollars (“CAD”), unless otherwise indicated. Mike Maguire, Interim Chief Executive Officer commented: “With 2024 complete High Arctic has effectively been reset and is now...

Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the “Animal Rule” Cash Runway to support planned operations into Q1 2026 Investor Update call today, March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the year ended December 31, 2024 and provided recent business highlights, with updates...